Aspirin Modulation of the Colorectal Cancer-Associated Microbe Fusobacterium nucleatum
Caitlin A. Brennan,
Geicho Nakatsu,
Carey Ann Gallini Comeau,
David A. Drew,
Jonathan N. Glickman,
Robert E. Schoen,
Andrew T. Chan,
Wendy S. Garrett
Affiliations
Caitlin A. Brennan
Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA
Geicho Nakatsu
Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA
Carey Ann Gallini Comeau
Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA
David A. Drew
Clinical and Translational Epidemiology Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
Jonathan N. Glickman
Department of Pathology, Harvard Medical School, Boston, Massachusetts, USA
Robert E. Schoen
Division of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
Andrew T. Chan
Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA
Wendy S. Garrett
Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA
There is an increasing understanding of the clinical correlations and potential mechanistic roles of specific members of the gut and tumoral microbiota in colorectal cancer (CRC) initiation, progression, and survival. However, we have yet to parlay this knowledge into better CRC outcomes through microbially informed diagnostic, preventive, or therapeutic approaches.
